{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:45:00Z","timestamp":1790084700527,"version":"4.0.1"},"reference-count":163,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Type 2 diabetes mellitus typically has the lipid features of elevated trigycerides, reduced HDL-cholesterol (both parts of the metabolic syndrome) and average or slightly elevated LDL-cholesterol. In consequence of hypertriglyceridemia, LDL particles are small and dense and therefore highly atherogenic. Outcome studies reveal that LDL-C lowering drugs have an above-average efficacy in type 2 diabetes as compared with non-diabetic patients. A minor increase of glycaemia in statin trials does not impair the beneficial cardiovascular results. Non-statin lipid lowering drugs do not impair glycaemia. Type 2 diabetes mellitus is now considered a major indication for lipid lowering drugs, thus there is a high value of and no major limitation for those compounds.<\/jats:p>","DOI":"10.1093\/ehjcvp\/pvaf076","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T11:31:37Z","timestamp":1760959897000},"page":"698-711","source":"Crossref","is-referenced-by-count":6,"title":["Management of dyslipidaemia in patients with comorbidities: facing the challenge: type 2 diabetes mellitus"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4677-9756","authenticated-orcid":false,"given":"Heinz","family":"Drexel","sequence":"first","affiliation":[{"name":"Academic Teaching Hospital Feldkirch, Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT) , Carinagasse 47, Feldkirch 6800 ,","place":["Austria"]},{"name":"Medical Faculty, Private University in the Principality of Liechtenstein , Dorfstrasse 24, Triesen 9495 ,","place":["Liechtenstein"]},{"name":"Vorarlberger Landeskrankenhausbetriebsgesellschaft , Carinagasse 47, Feldkirch 6800 ,","place":["Austria"]},{"name":"Drexel University College of Medicine , 2900 Queen Lane, Philadelphia PA 19129 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Festa","sequence":"additional","affiliation":[{"name":"Academic Teaching Hospital Feldkirch, Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT) , Carinagasse 47, Feldkirch 6800 ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen , 2200 Copenhagen ,","place":["Denmark"]},{"name":"Department of Emergency Medicine, Holbaek Hospital, University of Copenhagen , 2200 Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8304-6423","authenticated-orcid":false,"given":"Bianca","family":"Rocca","sequence":"additional","affiliation":[{"name":"Department of Medicine, LUM University , Casamassima (BA) 70010 \u00a0","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4612-117X","authenticated-orcid":false,"given":"Dobromir","family":"Dobrev","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology, West-German Heart and Vascular Centre, University Duisburg-Essen , DE 45122 Essen ,","place":["Germany"]},{"name":"Department of Medicine, Montreal Heart Institute and Universit\u00e9 de Montr\u00e9al \u00a0 Montr\u00e9al , H1Y 3N1","place":["Canada"]},{"name":"Department of Integrative Physiology, Baylor College of Medicine , Houston, TX 77030 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Agewall","sequence":"additional","affiliation":[{"name":"Institute of Clinical Sciences, Karolinska Institute, Danderyd Hospital , Stockholm 171 77 ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Tamargo","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, School of Medicine, Universidad Complutense, Instituto De Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n , Madrid 28040 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Kaser","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Medical University of Innsbruck , Anichstrasse 35, Innsbruck 6020 ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"2026051811264493500_pvaf076-B1","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1093\/ehjcvp\/pvae058","article-title":"Management of dyslipidaemia in patients with comorbidities: facing the challenge","volume":"10","author":"Mayer","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026051811264493500_pvaf076-B2","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1093\/ehjcvp\/pvae095","article-title":"Management of dyslipidaemia in patients with comorbidities-facing the challenge","volume":"11","author":"Fr\u00fchwald","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026051811264493500_pvaf076-B3","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1093\/ehjcvp\/pvaf023","article-title":"Management of dyslipidaemia in patients with comorbidities-facing the challenge: type 1 diabetes mellitus","volume":"11","author":"Kaser","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026051811264493500_pvaf076-B4"},{"key":"2026051811264493500_pvaf076-B5","doi-asserted-by":"publisher","first-page":"103869","DOI":"10.1016\/j.numecd.2025.103869","article-title":"Diabetes and risk of premature atherosclerotic cardiovascular disease","volume":"35","author":"Rana","year":"2025","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2026051811264493500_pvaf076-B6","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J"},{"key":"2026051811264493500_pvaf076-B7","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1038\/s41598-024-84985-x","article-title":"Contribution of type 2 diabetes to major adverse cardiovascular events (MACE) in a long-term observational study with different stages of atherosclerosis","volume":"15","author":"Mader","year":"2025","journal-title":"Sci Rep"},{"key":"2026051811264493500_pvaf076-B8","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"2026051811264493500_pvaf076-B9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s11892-019-1239-x","article-title":"Diabetes and cardiovascular disease: an update","volume":"19","author":"Almourani","year":"2019","journal-title":"Curr Diab Rep"},{"key":"2026051811264493500_pvaf076-B10","doi-asserted-by":"publisher","first-page":"37S","DOI":"10.1016\/j.amjmed.2003.08.012","article-title":"Obesity as a cardiovascular risk factor","volume":"115","author":"Sowers","year":"2003","journal-title":"Am J Med"},{"key":"2026051811264493500_pvaf076-B11","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.metabol.2014.04.003","article-title":"De novo lipogenesis in health and disease","volume":"63","author":"Ameer","year":"2014","journal-title":"Metabolism"},{"key":"2026051811264493500_pvaf076-B12","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/S0140-6736(63)91500-9","article-title":"The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus","volume":"1","author":"Randle","year":"1963","journal-title":"Lancet"},{"key":"2026051811264493500_pvaf076-B13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2026051811264493500_pvaf076-B14","doi-asserted-by":"publisher","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018. AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026051811264493500_pvaf076-B15","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1161\/01.ATV.0000032007.14355.21","article-title":"Relationship between cholesteryl ester transfer protein and atherogenic lipoprotein profile in morbidly obese women","volume":"22","author":"Ebenbichler","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026051811264493500_pvaf076-B16","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3390\/medicina58020299","article-title":"Atherosclerosis development and progression: the role of atherogenic small, dense LDL","volume":"58","author":"Vekic","year":"2022","journal-title":"Medicina"},{"key":"2026051811264493500_pvaf076-B17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.atherosclerosis.2021.05.010","article-title":"The LDL-C\/ApoB ratio predicts major cardiovascular events in patients with established atherosclerotic cardiovascular disease","volume":"329","author":"Drexel","year":"2021","journal-title":"Atherosclerosis"},{"key":"2026051811264493500_pvaf076-B18","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00125-003-1111-y","article-title":"Diabetic dyslipidaemia: from basic research to clinical practice","volume":"46","author":"Taskinen","year":"2003","journal-title":"Diabetologia"},{"key":"2026051811264493500_pvaf076-B19","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1530\/EJE-14-0195","article-title":"Association of HDL-C and apolipoprotein A-I with the risk of type 2 diabetes in subjects with impaired fasting glucose","volume":"171","author":"Hwang","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"2026051811264493500_pvaf076-B20","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1089\/ars.2009.2829","article-title":"Divergent effects of alpha-tocopherol and vitamin C on the generation of dysfunctional HDL associated with diabetes and the Hp 2\u20132 genotype","volume":"12","author":"Asleh","year":"2010","journal-title":"Antioxid Redox Signal"},{"key":"2026051811264493500_pvaf076-B21","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s10020-023-00715-5","article-title":"AGEs promote atherosclerosis by increasing LDL transcytosis across endothelial cells via RAGE\/NF-\u03baB\/Caveolin-1 pathway","volume":"29","author":"Shu","year":"2023","journal-title":"Mol Med"},{"key":"2026051811264493500_pvaf076-B22","doi-asserted-by":"publisher","first-page":"452","DOI":"10.2337\/diab.34.5.452","article-title":"Plasma apolipoproteins AI, AII, B, CI, and E are glucosylated in hyperglycemic diabetic subjects","volume":"34","author":"Curtiss","year":"1985","journal-title":"Diabetes"},{"key":"2026051811264493500_pvaf076-B23","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1007\/s00125-012-2570-9","article-title":"Advanced glycation end-products (AGEs) and functionality of reverse cholesterol transport in patients with type 2 diabetes and in mouse models","volume":"55","author":"Low","year":"2012","journal-title":"Diabetologia"},{"key":"2026051811264493500_pvaf076-B24","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1007\/s00125-007-0718-9","article-title":"Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties","volume":"50","author":"Hoang","year":"2007","journal-title":"Diabetologia"},{"key":"2026051811264493500_pvaf076-B25","doi-asserted-by":"publisher","first-page":"377","DOI":"10.2337\/diab.40.3.377","article-title":"Nonenzymatic glycosylation of HDL and impaired HDL-receptor-mediated cholesterol efflux","volume":"40","author":"Duell","year":"1991","journal-title":"Diabetes"},{"key":"2026051811264493500_pvaf076-B26","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1161\/CIRCRESAHA.119.312617","article-title":"HDL and reverse cholesterol transport","volume":"124","author":"Ouimet","year":"2019","journal-title":"Circ Res"},{"key":"2026051811264493500_pvaf076-B27","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/msj.20212","article-title":"Insulin resistance in obesity as the underlying cause for the metabolic syndrome","volume":"77","author":"Gallagher","year":"2010","journal-title":"Mt Sinai J Med"},{"key":"2026051811264493500_pvaf076-B28","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1172\/JCI25102","article-title":"Inflammation, stress, and diabetes","volume":"115","author":"Wellen","year":"2005","journal-title":"J Clin Invest"},{"key":"2026051811264493500_pvaf076-B29","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00592-014-0676-x","article-title":"NETosis is induced by high glucose and associated with type 2 diabetes","volume":"52","author":"Menegazzo","year":"2015","journal-title":"Acta Diabetol"},{"key":"2026051811264493500_pvaf076-B30","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.cmet.2011.07.015","article-title":"Insulin resistance, hyperglycemia, and atherosclerosis","volume":"14","author":"Bornfeldt","year":"2011","journal-title":"Cell Metab"},{"key":"2026051811264493500_pvaf076-B31","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.diabres.2014.04.006","article-title":"Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes","volume":"105","author":"Esser","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"2026051811264493500_pvaf076-B32","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.3390\/ijms26052196","article-title":"Diabetes-driven atherosclerosis: updated mechanistic insights and novel therapeutic strategies","volume":"26","author":"Karakasis","year":"2025","journal-title":"Int J Mol Sci"},{"key":"2026051811264493500_pvaf076-B33","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.3390\/ijms21051835","article-title":"The diabetes Mellitus-atherosclerosis connection: the role of lipid and glucose metabolism and chronic inflammation","volume":"21","author":"Poznyak","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026051811264493500_pvaf076-B34","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1089\/ars.2009.2569","article-title":"Evidence supporting a role for endoplasmic reticulum stress in the development of atherosclerosis in a hyperglycaemic mouse model","volume":"11","author":"Khan","year":"2009","journal-title":"Antioxid Redox Signal"},{"key":"2026051811264493500_pvaf076-B35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.5551\/jat.RV17014","article-title":"Mechanism of development of atherosclerosis and cardiovascular disease in diabetes Mellitus","volume":"25","author":"Katakami","year":"2018","journal-title":"J Atheroscler Thromb"},{"key":"2026051811264493500_pvaf076-B36","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1161\/CIRCULATIONAHA.112.127514","article-title":"Protein kinase C-\u03b2 contributes to impaired endothelial insulin signaling in humans with diabetes mellitus","volume":"127","author":"Tabit","year":"2013","journal-title":"Circulation"},{"key":"2026051811264493500_pvaf076-B37","doi-asserted-by":"publisher","first-page":"27","DOI":"10.5551\/jat.RV17014","article-title":"Mechanism of development of atherosclerosis and cardiovascular disease in diabetes Mellitus","volume":"25","author":"Katakami","year":"2018","journal-title":"J Atheroscler Thromb"},{"key":"2026051811264493500_pvaf076-B38","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis","volume":"371","author":"Cholesterol Treatment Trialists\u2019 (CTT) Collaborators","year":"2008","journal-title":"Lancet"},{"key":"2026051811264493500_pvaf076-B39","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","author":"Pedersen TR, Kjekshus J, Berg K, Haghfelt T, Faergeman O, Thorgeirsson G, Py\u00f6r\u00e4l\u00e4 K, Miettinen T, Wilhelmsen L, Olsson AG, Wedel H","year":"1994","journal-title":"Lancet"},{"key":"2026051811264493500_pvaf076-B40","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group","volume":"333","author":"Shepherd","year":"1995","journal-title":"N Engl J Med"},{"key":"2026051811264493500_pvaf076-B41","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1177\/204748730000700207","article-title":"Air Force\/Texas Coronary Atherosclerosis Prevention Study (AFCAPS\/TexCAPS): baseline characteristics and comparison with USA population","volume":"7","author":"Clearfield","year":"2000","journal-title":"J Cardiovasc Risk"},{"key":"2026051811264493500_pvaf076-B42","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"2026051811264493500_pvaf076-B43","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med"},{"key":"2026051811264493500_pvaf076-B44","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels","volume":"339","author":"Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group","year":"1998","journal-title":"N Engl J Med"},{"key":"2026051811264493500_pvaf076-B45","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"2026051811264493500_pvaf076-B46","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.2337\/dc05-2415","article-title":"Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the atorvastatin study for prevention of coronary heart disease endpoints in non-insulin-dependent diabetes mellitus (ASPEN)","volume":"29","author":"Knopp","year":"2006","journal-title":"Diabetes Care"},{"key":"2026051811264493500_pvaf076-B47","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","author":"Heart Protection Study Collaborative Group","year":"2002","journal-title":"Lancet"},{"key":"2026051811264493500_pvaf076-B48","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"MRC\/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial","volume":"361","author":"Collins","year":"2003","journal-title":"Lancet"},{"key":"2026051811264493500_pvaf076-B49","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1001\/jama.288.23.2998","article-title":"The antihypertensive and lipid-lowering treatment to prevent heart attack trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT)","volume":"288","author":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group","year":"2002","journal-title":"JAMA"},{"key":"2026051811264493500_pvaf076-B50","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","article-title":"Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial\u2013Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"key":"2026051811264493500_pvaf076-B51","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.2337\/diacare.28.5.1151","article-title":"Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial\u2013lipid-lowering arm (ASCOT-LLA)","volume":"28","author":"Sever","year":"2005","journal-title":"Diabetes Care"},{"key":"2026051811264493500_pvaf076-B52","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/S0140-6736(06)69472-5","article-title":"Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial","volume":"368","author":"Nakamura","year":"2006","journal-title":"Lancet"},{"key":"2026051811264493500_pvaf076-B53","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"key":"2026051811264493500_pvaf076-B54","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1056\/NEJMoa061894","article-title":"Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack","volume":"355","author":"Amarenco","year":"2006","journal-title":"N Engl J Med"},{"key":"2026051811264493500_pvaf076-B55","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1093\/ehjcvp\/pvab048","article-title":"Subgroup analyses in randomized clinical trials: value and limitations. Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapy","volume":"8","author":"Drexel","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026051811264493500_pvaf076-B56","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1093\/ehjcvp\/pvaa126","article-title":"The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid, diabetes, and antithrombotic trials","volume":"7","author":"Drexel","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026051811264493500_pvaf076-B57","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"2026051811264493500_pvaf076-B58","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","author":"Emerging Risk Factors Collaboration","year":"2010","journal-title":"Lancet"},{"key":"2026051811264493500_pvaf076-B59","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/S2213-8587(24)00040-8","article-title":"Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis","volume":"12","author":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026051811264493500_pvaf076-B60","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2147\/VHRM.S33664","article-title":"Ezetimibe therapy: mechanism of action and clinical update","volume":"8","author":"Phan","year":"2012","journal-title":"Vasc Health Risk Manag"},{"key":"2026051811264493500_pvaf076-B61","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/00041433-199706000-00003","article-title":"3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and hepatic apolipoprotein B secretion","volume":"8","author":"Huff","year":"1997","journal-title":"Curr Opin Lipidol"},{"key":"2026051811264493500_pvaf076-B62","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1517\/13543784.11.11.1587","article-title":"Ezetimibe","volume":"11","author":"Bays","year":"2002","journal-title":"Expert Opin Investig Drugs"},{"key":"2026051811264493500_pvaf076-B63","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1097\/MOL.0b013e32833c1f16","article-title":"Combination regimens with statin, niacin, and intestinally active LDL-lowering drugs: alternatives to high-dose statin therapy?","volume":"21","author":"Guyton","year":"2010","journal-title":"Curr Opin Lipidol"},{"key":"2026051811264493500_pvaf076-B64","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.atherosclerosis.2021.03.039","article-title":"Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: a statement from a European Atherosclerosis Society Task Force","volume":"325","author":"Averna","year":"2021","journal-title":"Atherosclerosis"},{"key":"2026051811264493500_pvaf076-B65","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/j.1365-2796.2008.02062.x","article-title":"Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials","volume":"265","author":"Pandor","year":"2009","journal-title":"J Intern Med"},{"key":"2026051811264493500_pvaf076-B66","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.4065\/81.12.1579","article-title":"Ezetimibe\/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study","volume":"81","author":"Goldberg","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"2026051811264493500_pvaf076-B67","doi-asserted-by":"publisher","first-page":"818","DOI":"10.4093\/dmj.2023.0171","article-title":"The efficacy and safety of moderate-intensity rosuvastatin with ezetimibe versus high-intensity rosuvastatin in high atherosclerotic cardiovascular disease risk patients with type 2 diabetes Mellitus: a randomized, multicenter, open, parallel, phase 4 study","volume":"47","author":"Moon","year":"2023","journal-title":"Diabetes Metab J"},{"key":"2026051811264493500_pvaf076-B68","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s13300-020-00778-1","article-title":"Comparison of the efficacy and safety of rosuvastatin\/ezetimibe combination therapy and rosuvastatin monotherapy on lipoprotein in patients with type 2 diabetes: multicenter randomized controlled study","volume":"11","author":"Lee","year":"2020","journal-title":"Diabetes Ther"},{"key":"2026051811264493500_pvaf076-B69","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1056\/NEJMoa0800742","article-title":"Simvastatin with or without ezetimibe in familial hypercholesterolemia","volume":"358","author":"Kastelein","year":"2008","journal-title":"N Engl J Med"},{"key":"2026051811264493500_pvaf076-B70","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1016\/j.jacc.2008.10.031","article-title":"Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial","volume":"52","author":"Fleg","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2026051811264493500_pvaf076-B71","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1056\/NEJMoa0804602","article-title":"Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis","volume":"359","author":"Rosseb\u00f8","year":"2008","journal-title":"N Engl J Med"},{"key":"2026051811264493500_pvaf076-B72","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"2026051811264493500_pvaf076-B73","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1161\/CIRCULATIONAHA.117.030950","article-title":"Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes Mellitus: results from IMPROVE-IT (improved reduction of outcomes: vytorin efficacy international trial)","volume":"137","author":"Giugliano","year":"2018","journal-title":"Circulation"},{"key":"2026051811264493500_pvaf076-B74","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1093\/eurheartj\/ehac709","article-title":"Moderate-intensity statin with ezetimibe vs. high-intensity statin in patients with diabetes and atherosclerotic cardiovascular disease in the RACING trial","volume":"44","author":"Lee","year":"2023","journal-title":"Eur Heart J"},{"key":"2026051811264493500_pvaf076-B75","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1210\/clinem\/dgad714","article-title":"Comparison of the efficacy of ezetimibe combination therapy and high-intensity statin monotherapy in type 2 diabetes","volume":"109","author":"Park","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026051811264493500_pvaf076-B76","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1001\/jamacardio.2024.3911","article-title":"Alternative LDL cholesterol-lowering strategy vs high-intensity statins in atherosclerotic cardiovascular disease: a systematic review and individual patient data meta-analysis","volume":"10","author":"Lee","year":"2025","journal-title":"JAMA Cardiol"},{"key":"2026051811264493500_pvaf076-B77","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1093\/ehjacc\/zuac123","article-title":"Acute LDL-C reduction post ACS: strike early and strike strong: from evidence to clinical practice. A clinical consensus statement of the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Association of Preventive Cardiology (EAPC) and the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy","volume":"11","author":"Krychtiuk","year":"2022","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2026051811264493500_pvaf076-B78","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"2026051811264493500_pvaf076-B79","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"2026051811264493500_pvaf076-B80","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.jacl.2018.03.088","article-title":"Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: results from the SPIRE randomized trials of bococizumab","volume":"12","author":"Ridker","year":"2018","journal-title":"J Clin Lipidol"},{"key":"2026051811264493500_pvaf076-B81","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1093\/ehjcvp\/pvad019","article-title":"The efficacy of PCSK9 inhibitors on major cardiovascular events and lipid profile in patients with diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"9","author":"Imbalzano","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026051811264493500_pvaf076-B82","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","article-title":"Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial","volume":"5","author":"Sabatine","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026051811264493500_pvaf076-B83","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.122.061620","article-title":"Long-term evolocumab in patients with established atherosclerotic cardiovascular disease","volume":"146","author":"O'Donoghue","year":"2022","journal-title":"Circulation"},{"key":"2026051811264493500_pvaf076-B84","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/S2213-8587(19)30158-5","article-title":"Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial","volume":"7","author":"Ray","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026051811264493500_pvaf076-B85","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1161\/CIRCULATIONAHA.119.043826","article-title":"Effect of alirocumab on stroke in ODYSSEY OUTCOMES","volume":"140","author":"Jukema","year":"2019","journal-title":"Circulation"},{"key":"2026051811264493500_pvaf076-B86","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1093\/ehjcvp\/pvae025","article-title":"Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation","volume":"10","author":"Goodman","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026051811264493500_pvaf076-B87","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S2213-8587(22)00353-9","article-title":"Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial","volume":"11","author":"Ray","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026051811264493500_pvaf076-B88","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.7573\/dic.2023-12-3","article-title":"Inclisiran for the treatment of hypercholesterolaemia","volume":"13","author":"Marrs","year":"2024","journal-title":"Drugs Context"},{"key":"2026051811264493500_pvaf076-B89","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1111\/dom.15650","article-title":"Inclisiran in individuals with diabetes or obesity: post hoc pooled analyses of the ORION-9, ORION-10 and ORION-11 phase 3 randomized trials","volume":"26","author":"Leiter","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"2026051811264493500_pvaf076-B90","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2337\/dc18-1491","article-title":"Inclisiran lowers LDL-C and PCSK9 irrespective of diabetes Status: the ORION-1 randomized clinical trial","volume":"42","author":"Leiter","year":"2019","journal-title":"Diabetes Care"},{"key":"2026051811264493500_pvaf076-B91","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"2026051811264493500_pvaf076-B92","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1016\/j.jacc.2023.10.007","article-title":"Safety and tolerability of inclisiran for treatment of hypercholesterolemia in 7 clinical trials","volume":"82","author":"Wright","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026051811264493500_pvaf076-B93","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Outcomes Investigators","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"2026051811264493500_pvaf076-B94","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1177\/2047487319864671","article-title":"Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy","volume":"27","author":"Ballantyne","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"2026051811264493500_pvaf076-B95","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/ehjcvp\/pvad052","article-title":"Cardiovascular events in patients treated with bempedoic acid vs. Placebo: systematic review and meta-analysis","volume":"9","author":"Mutschlechner","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026051811264493500_pvaf076-B96","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1001\/jama.2023.9696","article-title":"Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients","volume":"330","author":"Nissen","year":"2023","journal-title":"JAMA"},{"key":"2026051811264493500_pvaf076-B97","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/dom.14645","article-title":"Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: a post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials","volume":"24","author":"Leiter","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"2026051811264493500_pvaf076-B98","doi-asserted-by":"publisher","first-page":"pvaf012","DOI":"10.1093\/ehjcvp\/pvaf012","article-title":"New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024","volume":"11","author":"Tamargo","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026051811264493500_pvaf076-B99","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/ehjcvp\/pvad074","article-title":"Novel therapeutic targets and emerging treatments for atherosclerotic cardiovascular disease","volume":"10","author":"Zheng","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026051811264493500_pvaf076-B100","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1093\/ehjcvp\/pvae033","article-title":"Should pharmacotherapy targeting lipoprotein(a) be further expanded for patients with diabetes?","volume":"10","author":"Sun","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026051811264493500_pvaf076-B101","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s12020-020-02190-y","article-title":"Effects of metformin on blood lipid profiles in nondiabetic adults: a meta-analysis of randomized controlled trials","volume":"67","author":"Weng","year":"2020","journal-title":"Endocrine"},{"key":"2026051811264493500_pvaf076-B102","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2026051811264493500_pvaf076-B103","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2026051811264493500_pvaf076-B104","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1080\/03007995.2016.1238354","article-title":"Real world clinical outcomes and patient characteristics for canagliflozin treated patients in a specialty diabetes clinic","volume":"33","author":"Johnson","year":"2017","journal-title":"Curr Med Res Opin"},{"key":"2026051811264493500_pvaf076-B105","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.dsx.2019.01.016","article-title":"Lipid profile in type 2 diabetic patients with new dapagliflozin treatment; actual clinical experience data of six months retrospective lipid profile from single center","volume":"13","author":"Calapkulu","year":"2019","journal-title":"Diabetes Metab Syndr"},{"key":"2026051811264493500_pvaf076-B106","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.2337\/dc12-2491","article-title":"Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial","volume":"36","author":"Schernthaner","year":"2013","journal-title":"Diabetes Care"},{"key":"2026051811264493500_pvaf076-B107","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12933-017-0608-5","article-title":"Correction to: dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin","volume":"16","author":"Hayashi","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"2026051811264493500_pvaf076-B108","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1161\/ATVBAHA.118.311339","article-title":"Mechanism of increased LDL (low-density lipoprotein) and decreased triglycerides with SGLT2 (Sodium-Glucose Cotransporter 2) inhibition","volume":"38","author":"Basu","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026051811264493500_pvaf076-B109","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1111\/dom.16202","article-title":"Dapagliflozin modulates hepatic lipid metabolism through the proprotein convertase subtilisin\/kexin type 9\/low density lipoprotein receptor pathway","volume":"27","author":"Lu","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"2026051811264493500_pvaf076-B110","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1093\/ehjcvp\/pvae045","article-title":"Comparative cardiovascular and renal effectiveness of empagliflozin and dapagliflozin: scandinavian cohort study","volume":"10","author":"Engstr\u00f6m","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026051811264493500_pvaf076-B111","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1111\/j.1463-1326.2007.00715.x","article-title":"Effects of pioglitazone on lipid and lipoprotein metabolism","volume":"9","author":"Betteridge","year":"2007","journal-title":"Diabetes Obes Metab"},{"key":"2026051811264493500_pvaf076-B112","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/j.1464-5491.2004.01258.x","article-title":"Sustained effects of pioglitazone vs. Glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with type 2 diabetes","volume":"21","author":"Tan","year":"2004","journal-title":"Diabet Med"},{"key":"2026051811264493500_pvaf076-B113","doi-asserted-by":"publisher","first-page":"6068","DOI":"10.1210\/jc.2003-030861","article-title":"Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial","volume":"89","author":"Schernthaner","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2026051811264493500_pvaf076-B114","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s00125-005-0092-4","article-title":"The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients","volume":"49","author":"Majali","year":"2006","journal-title":"Diabetologia"},{"key":"2026051811264493500_pvaf076-B115","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.2337\/diacare.28.7.1547","article-title":"A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia","volume":"28","author":"Goldberg","year":"2005","journal-title":"Diabetes Care"},{"key":"2026051811264493500_pvaf076-B116","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.2337\/dc06-1903","article-title":"Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia","volume":"30","author":"Deeg","year":"2007","journal-title":"Diabetes Care"},{"key":"2026051811264493500_pvaf076-B117","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"2026051811264493500_pvaf076-B118","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","article-title":"Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes","volume":"392","author":"McGuire","year":"2025","journal-title":"N Engl J Med"},{"key":"2026051811264493500_pvaf076-B119","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"key":"2026051811264493500_pvaf076-B120","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2026051811264493500_pvaf076-B121","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"2026051811264493500_pvaf076-B122","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1056\/NEJMoa2204601","article-title":"Once-weekly dulaglutide for the treatment of youths with type 2 diabetes","volume":"387","author":"Arslanian","year":"2022","journal-title":"N Engl J Med"},{"key":"2026051811264493500_pvaf076-B123","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"N Engl J Med"},{"key":"2026051811264493500_pvaf076-B124","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"key":"2026051811264493500_pvaf076-B125","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"key":"2026051811264493500_pvaf076-B126","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"2026051811264493500_pvaf076-B127","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"key":"2026051811264493500_pvaf076-B128","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2026051811264493500_pvaf076-B129","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"2026051811264493500_pvaf076-B130","doi-asserted-by":"publisher","first-page":"e076410","DOI":"10.1136\/bmj-2023-076410","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis","volume":"384","author":"Yao","year":"2024","journal-title":"BMJ"},{"key":"2026051811264493500_pvaf076-B131","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1007\/s00125-009-1611-5","article-title":"The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice","volume":"53","author":"Hsieh","year":"2010","journal-title":"Diabetologia"},{"key":"2026051811264493500_pvaf076-B132","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1161\/ATVBAHA.118.310990","article-title":"Liraglutide reduces postprandial hyperlipidemia by increasing ApoB48 (apolipoprotein B48) catabolism and by reducing ApoB48 production in patients with type 2 diabetes Mellitus","volume":"38","author":"Verg\u00e8s","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026051811264493500_pvaf076-B133","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1007\/s00125-022-05765-8","article-title":"Intestinal lipid absorption and transport in type 2 diabetes","volume":"65","author":"Verg\u00e8s","year":"2022","journal-title":"Diabetologia"},{"key":"2026051811264493500_pvaf076-B134","doi-asserted-by":"publisher","first-page":"e49152","DOI":"10.1371\/journal.pone.0049152","article-title":"GLP-1 receptor activation inhibits VLDL production and reverses hepatic steatosis by decreasing hepatic lipogenesis in high-fat-fed APOE*3-Leiden mice","volume":"7","author":"Parlevliet","year":"2012","journal-title":"PLoS One"},{"key":"2026051811264493500_pvaf076-B135","doi-asserted-by":"publisher","first-page":"238","DOI":"10.2174\/1573399810666140707092506","article-title":"Effect of GLP-1 based therapies on diabetic dyslipidemia","volume":"10","author":"Patel","year":"2014","journal-title":"Curr Diabetes Rev"},{"key":"2026051811264493500_pvaf076-B136","doi-asserted-by":"publisher","first-page":"10164","DOI":"10.3390\/ijms241210164","article-title":"Antidiabetic agents and their effects on lipid profile: a single shot for several cardiovascular targets","volume":"24","author":"Piccirillo","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026051811264493500_pvaf076-B137","doi-asserted-by":"publisher","first-page":"e2386","DOI":"10.1097\/MD.0000000000002386","article-title":"Effects of sitagliptin on lipid profiles in patients with type 2 diabetes Mellitus: a meta-analysis of randomized clinical trials","volume":"95","author":"Fan","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"2026051811264493500_pvaf076-B138","doi-asserted-by":"publisher","first-page":"103633","DOI":"10.1016\/j.amsu.2022.103633","article-title":"Effects of novel glucose-lowering drugs on the lipid parameters: a systematic review and meta-analysis","volume":"77","author":"Dar","year":"2022","journal-title":"Ann Med Surg"},{"key":"2026051811264493500_pvaf076-B139","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.bbrc.2017.02.071","article-title":"Dipeptidyl peptidase-4 impairs insulin signaling and promotes lipid accumulation in hepatocytes","volume":"485","author":"Rufinatscha","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"2026051811264493500_pvaf076-B140","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.2337\/db14-0804","article-title":"Dipeptidyl peptidase-4 inhibition ameliorates Western diet-induced hepatic steatosis and insulin resistance through hepatic lipid remodeling and modulation of hepatic mitochondrial function","volume":"64","author":"Aroor","year":"2015","journal-title":"Diabetes"},{"key":"2026051811264493500_pvaf076-B141","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.12659\/MSM.900033","article-title":"The effect of sitagliptin on lipid metabolism of fatty liver mice and related mechanisms","volume":"23","author":"Xu","year":"2017","journal-title":"Med Sci Monit"},{"key":"2026051811264493500_pvaf076-B142","doi-asserted-by":"publisher","first-page":"10164","DOI":"10.3390\/ijms241210164","article-title":"Novel antidiabetic agents and their effects on lipid profile: a single shot for several cardiovascular targets","volume":"24","author":"Piccirillo","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026051811264493500_pvaf076-B143","first-page":"245","article-title":"The effect of glipizide on HDL and HDL subclasses","volume":"3","author":"Bergman","year":"1986","journal-title":"Diabetes Res"},{"key":"2026051811264493500_pvaf076-B144","first-page":"394","article-title":"One year comparative trial of metformin and glipizide in type 2 diabetes mellitus","volume":"20","author":"Campbell","year":"1994","journal-title":"Diabete Metab"},{"key":"2026051811264493500_pvaf076-B145","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/j.1462-8902.2004.00325.x","article-title":"The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes","volume":"6","author":"Buse","year":"2004","journal-title":"Diabetes Obes Metab"},{"key":"2026051811264493500_pvaf076-B146","first-page":"246","article-title":"Effect of gliclazide on plasma lipids and pancreatic beta cell function in non-insulin-dependent diabetes mellitus","volume":"16","author":"Chen","year":"1993","journal-title":"Changgeng Yi Xue Za Zhi"},{"key":"2026051811264493500_pvaf076-B147","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1185\/03007998609111102","article-title":"Is sulphonylurea therapy effective long term? A 3-year study with gliclazide","volume":"10","author":"Zurro Hernandez","year":"1986","journal-title":"Curr Med Res Opin"},{"key":"2026051811264493500_pvaf076-B148","first-page":"1060","article-title":"Efficacy and safety of gliclazide in the treatment of non-insulin-dependent diabetes mellitus: a Canadian multicenter study","volume":"15","author":"Mailhot","year":"1993","journal-title":"Clin Ther"},{"key":"2026051811264493500_pvaf076-B149","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1185\/030079901750120231","article-title":"Comparison of acarbose and gliclazide as first-line agents in patients with type 2 diabetes","volume":"16","author":"Salman","year":"2001","journal-title":"Curr Med Res Opin"},{"key":"2026051811264493500_pvaf076-B150","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.2337\/diacare.27.11.2597","article-title":"Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function","volume":"27","author":"Li","year":"2004","journal-title":"Diabetes Care"},{"key":"2026051811264493500_pvaf076-B151","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1476-511X-12-54","article-title":"Effect of insulin analog initiation therapy on LDL\/HDL subfraction profile and HDL associated enzymes in type 2 diabetic patients","volume":"12","author":"Aslan","year":"2013","journal-title":"Lipids Health Dis"},{"key":"2026051811264493500_pvaf076-B152","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.atherosclerosis.2014.05.942","article-title":"Insulin-induced glucose control improves HDL cholesterol levels but not reverse cholesterol transport in type 2 diabetic patients","volume":"235","author":"Fadini","year":"2014","journal-title":"Atherosclerosis"},{"key":"2026051811264493500_pvaf076-B153","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1161\/01.ATV.3.4.339","article-title":"Insulin-mediated increases in the HDL cholesterol\/cholesterol ratio in humans","volume":"3","author":"Sadur","year":"1983","journal-title":"Arteriosclerosis"},{"key":"2026051811264493500_pvaf076-B154","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1172\/JCI117633","article-title":"Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans","volume":"95","author":"Lewis","year":"1995","journal-title":"J Clin Invest"},{"key":"2026051811264493500_pvaf076-B155","doi-asserted-by":"publisher","first-page":"580","DOI":"10.2337\/db09-1297","article-title":"Insulin acutely inhibits intestinal lipoprotein secretion in humans in part by suppressing plasma free fatty acids","volume":"59","author":"Pavlic","year":"2010","journal-title":"Diabetes"},{"key":"2026051811264493500_pvaf076-B156","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.metabol.2011.09.014","article-title":"Effects of hyperinsulinemia on lipoprotein lipase, angiopoietin-like protein 4, and glycosylphosphatidylinositol-anchored high-density lipoprotein binding protein 1 in subjects with and without type 2 diabetes mellitus","volume":"61","author":"Ruge","year":"2012","journal-title":"Metabolism"},{"key":"2026051811264493500_pvaf076-B157","doi-asserted-by":"publisher","first-page":"9030","DOI":"10.1016\/S0021-9258(18)81898-1","article-title":"Insulin regulation of lipoprotein lipase activity in 3T3-L1 adipocytes is mediated at posttranscriptional and posttranslational levels","volume":"264","author":"Semenkovich","year":"1989","journal-title":"J Biol Chem"},{"key":"2026051811264493500_pvaf076-B158","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/0026-0495(95)90193-0","article-title":"Change in skeletal muscle lipoprotein lipase activity in response to insulin\/glucose in non-insulin-dependent diabetes mellitus","volume":"44","author":"Yost","year":"1995","journal-title":"Metabolism"},{"key":"2026051811264493500_pvaf076-B159","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/0026-0495(91)90178-Y","article-title":"Tissue-specific regulation of lipoprotein lipase activity by insulin\/glucose in normal-weight humans","volume":"40","author":"Farese","year":"1991","journal-title":"Metabolism"},{"key":"2026051811264493500_pvaf076-B160","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1172\/JCI110547","article-title":"Insulin stimulation of adipose tissue lipoprotein lipase. Use of the euglycemic clamp technique","volume":"69","author":"Sadur","year":"1982","journal-title":"J Clin Invest"},{"key":"2026051811264493500_pvaf076-B161","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/BF00304851","article-title":"Response of adipose tissue lipoprotein lipase activity and serum lipoproteins to acute hyperinsulinaemia in man","volume":"27","author":"Yki-J\u00e4rvinen","year":"1984","journal-title":"Diabetologia"},{"key":"2026051811264493500_pvaf076-B162","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1172\/JCI118786","article-title":"The expression of ob gene is not acutely regulated by insulin and fasting in human abdominal subcutaneous adipose tissue","volume":"98","author":"Vidal","year":"1996","journal-title":"J Clin Invest"},{"key":"2026051811264493500_pvaf076-B163","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1161\/CIRCULATIONAHA.120.045373","article-title":"Insulin prevents hypercholesterolemia by suppressing 12\u03b1-hydroxylated bile acids","volume":"145","author":"Semova","year":"2022","journal-title":"Circulation"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvaf076\/64957128\/pvaf076.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/11\/8\/698\/64957128\/pvaf076.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/11\/8\/698\/64957128\/pvaf076.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T15:26:56Z","timestamp":1779118016000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/11\/8\/698\/8304007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":163,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,10,27]]},"published-print":{"date-parts":[[2025,12,16]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvaf076","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,10,27]]}}}